Drug intelligence / Profile preview

CNK-UT006

Development stage: Preclinical
Lead developer: ST Phi Therapeutics
Modality: Cell Therapies
Administration: Intravenous

Overview

CNK-UT006 is an allogeneic T-cell therapy being developed by ST Phi Therapeutics for the treatment of triple-negative breast cancer (TNBC). The therapy utilizes T cells engineered with a chimeric NK receptor (CNK) designed to recognize natural killer (NK) cell receptor ligands expressed on the surface of tumor cells. Upon binding to these ligands, the engineered T cells mediate the targeted elimination of tumor cells. As an allogeneic "off-the-shelf" product, CNK-UT006 is intended to provide a more accessible alternative to autologous cell therapies. The program is currently in the preclinical stage of development.

Other names: CNK-UT

Targets

NKp44L (NKp44 ligand)MICB (Major histocompatibility complex class i-related protein B)B7-H3

Beyond the preview

Go deeper on CNK-UT006.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CNK-UT006.

Explore the full profile